sphingolipidosis


Also found in: Encyclopedia.

sphingolipidosis

 [sfing″go-lip″ĭ-do´sis]
a general designation applied to diseases characterized by abnormal storage of sphingolipids, such as gaucher's disease, niemann-pick disease, hurler's syndrome, and tay-sachs disease; all are associated with mental retardation and premature death.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

sphin·go·lip·i·do·sis

(sfing'gō-lip'i-dō'sis),
Collective designation for various diseases characterized by abnormal sphingolipid metabolism (for example, gangliosidosis, Gaucher disease, Niemann-Pick disease).
Farlex Partner Medical Dictionary © Farlex 2012

sphingolipidosis

(sfĭng′gō-lĭp′ĭ-dō′sĭs)
n.
Any of various diseases, such as Gaucher disease or Niemann-Pick disease, caused by a deficiency of an enzyme that degrades sphingolipids.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.

sphin·go·lip·i·do·sis

, sphingolipodystrophy, pl. sphingolipidoses (sfinggō-lipi-dōsis, -ō-distrŏ-fē, -i-dōsēz)
Collective designation for a variety of diseases characterized by abnormal sphingolipid metabolism, e.g., gangliosidosis, Gaucher disease, Niemann-Pick disease.
Medical Dictionary for the Health Professions and Nursing © Farlex 2012

sphin·go·lip·i·do·sis

, pl. sphingo lipidoses , sphingolipodystro phy (sfinggō-lipi-dōsis, -i-dōsēz, -ō-distrŏ-fē)
Collective designation for various diseases characterized by abnormal sphingolipid metabolism.
Medical Dictionary for the Dental Professions © Farlex 2012
References in periodicals archive ?
In general, they are a group of relatively rare inborn errors of metabolism resulting in accumulation of sphingolipids (sphingolipidosis) caused by defects in the genes coding for proteins taking part in the lysosomal degradation of sphingolipids [23].
Arsenic induces oxidative stress, sphingolipidosis, depletes proteins and some antioxidants in various regions of rat brain.
In contrast to the enzymes administered in ERT, the drug used for SRT can cross the blood-brain barrier and reach target cells in the brain and thus could be used in the treatment of sphingolipidosis with involvement of the central nervous system (7).